Literature DB >> 6653400

Steroid D-ring glucuronides: characterization of a new class of cholestatic agents.

M Vore, C Montgomery, M Meyers.   

Abstract

In summary, we have shown that steroid D-ring, but not steroid A-ring, glucuronide conjugates act at the level of the bile canaliculus to decrease bile-acid-dependent flow, initially; and subsequently, bile-acid-independent flow. These data indicate that glucuronide conjugates are not necessarily inactive; the present glucuronides clearly possess toxicological activity. The cholestatic glucuronides are all natural, endogenously formed products of metabolism. The critical questions which remain are whether metabolism of steroids to D-ring glucuronides is an obligatory step in the etiology of steroid-induced cholestasis and whether these glucuronides, at concentrations attained in humans, are capable of decreasing hepatic excretory function and inducing morphological and biochemical changes of clinical importance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653400     DOI: 10.3109/03602538308991419

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  3 in total

1.  Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2007-09-29       Impact factor: 2.668

Review 2.  The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.

Authors:  Anna Radominska-Pandya; Stacie M Bratton; Matthew R Redinbo; Michael J Miley
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

3.  Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2008-02-03       Impact factor: 2.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.